Abstract
ObjectiveThe purpose of this study is to compare the difference of clinical efficacy between conventional intraperitoneal chemotherapy and HIPEC, so as to explore the clinical application value and advantages of HIPEC.DesignA retrospective analysis was conducted on 80 patients with malignant ascites admitted to our hospital from June 2017 to June 2019. The general clinical data and qualitative data of the treatment results of 80 patients with malignant ascites were processed by SPSS19.0 using χ2 test, and quantitative data were processed by t test. P < 0.05, statistical data can be considered statistically significant.ResultsThere was no significant change in vital signs and temperature in the observation group during the treatment, and the difference was not statistically significant.The short-term total effective rate of patients in the observation group was 91.11%, and the short-term total effective rate of the patients in the control group was 40%.There was no significant difference in the incidence of adverse reactions between the two groups of patients.ConclusionIntraperitoneal hyperthermic chemotherapy combined with intravenous chemotherapy can significantly control malignant ascites and has small adverse reactions, which is worthy of clinical promotion and application.
Highlights
Abdominal or systemic malignant tumors can induce diffuse lesion of the abdominal visceral wall and further lead to abnormal increase of peritoneal effusion, which is called malignant ascites clinically [1]
Intraperitoneal hyperthermic chemotherapy combined with intravenous chemotherapy can significantly control malignant ascites and has small adverse reactions, which is worthy of clinical promotion and application
In the observation group, 45 patients were first treated with hyperthermic intraperitoneal chemotherapy (HIPEC) for 5 times, followed by 6 ~ 8 courses of intravenous chemotherapy
Summary
Abdominal or systemic malignant tumors can induce diffuse lesion of the abdominal visceral wall and further lead to abnormal increase of peritoneal effusion, which is called malignant ascites clinically [1]. Clinical studies have found that malignant ascites develops rapidly, and patients without effective intervention may experience symptoms such as abdominal distention, abdominal pain, and even breathing difficulties [2]. Jiao et al World Journal of Surgical Oncology (2020) 18:180 intraperitoneal chemotherapy and HIPEC, so as to explore the clinical application value and advantages of HIPEC
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
